Phathom Pharmaceuticals (PHAT)
(Real Time Quote from BATS)
$8.66 USD
+0.31 (3.71%)
Updated Aug 4, 2025 02:56 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Phathom Pharmaceuticals, Inc. has a market cap of $582.95M, which represents its share price of $8.35 multiplied by its outstanding shares number of 69.81M. As a small-cap company, PHAT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PHAT 8.66 +0.31(3.71%)
Will PHAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?
Other News for PHAT
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business ...
Phathom Pharmaceuticals Insider Makes Notable Stock Sale
Avidity, Phathom mentioned as potential takeout targets at Needham
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
Phathom Pharmaceuticals (PHAT) Appoints New Chief Legal Officer | PHAT Stock News